Ernexa Therapeutics Inc.(ERNA)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
Ernexa Therapeutics Inc. (ERNA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ERNA at 10.6/100 on a 32-signal composite quality model, placing it at rank #2,907 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Ernexa Therapeutics Inc. reports net income of $-4.0M, free cash flow of $-4.2M. Top institutional holders of ERNA by reported 13-F value include CITADEL ADVISORS, VANGUARD FIDUCIARY, Dauntless Investment Group, based on the most recent SEC filings. ERNA trades on the Nasdaq exchange and files with the SEC under CIK 748592. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ERNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ernexa Therapeutics Inc. directly from SEC EDGAR.
AI Quality Score
10.6/100
AI Rank
#2,907
Net Income
$-4.0M
Free Cash Flow
$-4.2M
ERNA key financials by period
Ernexa Therapeutics Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2024
10-K
$582.0K
$-44.5M
—
FY 2023
10-K
$68.0K
$-21.7M
—
FY 2020
10-K/A
$5.8M
$-7.3M
-125.0%
FY 2019
10-K/A
$19.8M
$-2.0M
-8.9%
FY 2018
10-K
$23.3M
$-259.0K
0.9%
FY 2017
10-K
$21.3M
$-1.1M
-6.6%
Institutions holding ERNA
Institutional investors reporting a position in Ernexa Therapeutics Inc. on SEC Form 13F.
